Aman Jaiswar

Smart Pulse Oximeters Market Estimated to Expand at a Robust CAGR by 2026

2019-09-05T18:02:48.524Z

Hypoxemia is a common complication of childhood infections, particularly pneumonia. Pneumonia effects developing countries excessively, and accounted for over 2 million deaths per year globally. Hypoxemia is a recognized risk factor for death, and associates with disease severity and is hard to detect until onset of cyanosis. Smart pulse oximeter has been developed using a commercial wireless pulse oximeter and custom software for laptop, smartphone or computer. User friendly software has signal processing algorithms for heart rate, respiratory rate, and oxygen saturation from the plethysmographic waveform. Training module and clinical rules are under development. Increasing prevalence of cardiovascular disorders such as congestive heart failure, high blood pressure, coronary artery disease, cardiac arrest, arrhythmia, stroke, congenital heart diseases, and peripheral artery disease is expected to fuel the growth of smart pulse oximeters market during the forecast period.

The Smart Pulse Oximeters Market is categorized on the basis of product, end-users, and region. On the basis of products smart pulse oximeters market is categorized into finger pulse oximeters, handheld pulse oximeters, wrist pulse oximeters, table top pulse oximeters and wireless pulse oximeters. Finger pulse oximeters are the devices that measures oxygen saturation level of arterial blood utilizing a sensor connected to finger. These are smaller in size as compare to other product types of smart pulse oximeters. Finger pulse oximeters can be used in each type of end users like hospitals, clinics, ambulatory surgical centers, and home care setting. Finger pulse oximeters is easy to use as there is no need to attach any external probe or sensor.

Comparatively having low cost among all type of smart pulse oximeters so finger Pulse oximeters has highest demand in global smart pulse oximeters market. Most preferable type of smart pulse oximeters by clinicians and recommended for sports man and athletes for their regular checkup of oxygen blood saturation level. Handheld pulse oximeters measures the SpO2 level, arterial blood pressure, and pulse rate of an individual sensor connected to finger or an ear lobe or forehead and by connecting neonatal sensor and infant sensor in children and new born babies. Based on end-users the global smart pulse oximeters market is categorized into specialty clinics, hospitals, ambulatory surgical centers, home care settings, and others

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=50310

Based on geography, the Smart pulse oximeters market can be segmented into five major regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Further North America smart pulse oximeters market is segmented in to U.S., and Canada. Europe smart pulse oximeters market is segmented into U.K., Germany, France, Italy, Spain, and Rest of Europe. Asia pacific smart pulse oximeters market is further segmented into Japan, India, China, Australia & New Zealand, and Rest of Asia Pacific. Latin America smart pulse oximeters market is segmented into Mexico, Brazil, and Rest of Latin America.

Where Middle East and Africa smart pulse oximeters market is segmented into Saudi Arabia, South Africa, Israel, and Rest of Middle East and Africa. North America dominated the global smart pulse oximeters due to factors such as frequent lifestyle associated changes, advanced diagnosis system, high disposable income, increasing prevalence of cardiovascular diseases, and rising geriatric population. Moreover, increasing government initiatives to create awareness and need for better healthcare infrastructure are the factors contributing to the growth of smart pulse oximeters market during the forecast period. Asia-Pacific region is anticipated to grow at faster rate during the forecast period owing to the factors such as improving healthcare infrastructure, increasing patient awareness, and rising disposable income.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=50310

Some of the major key players in global smart pulse oximeters market are Masimo, Medtronic, Nonnin Medical, Smiths Medical, Koninklijke Philips N.V., Nihon Kohden Corporation, Hill-Rom Services Inc., Contec Medical Systems Co., Ltd., and Mindray

Micromanipulators Market Pegged for Robust Expansion by 2026

2019-09-05T18:02:48.114Z

The global Micromanipulators Market is expected to increase rapidly in the years to come due to the increasing adoption of various types of treatment to increase infertility in males. The micromanipuator market is presumed to have larger application in the medical sector. Various advanced technique may be performed with the help of micromanipulation. Apart from that, neurology and cell biology is also expected to open up new approach in research and development. Manufacturers may offer micromanipulator devices with advanced technical procedures at better prices in the forecast period 2018-2026.

The global micromanipulators market could be segmented into product type, end user and by application. On the basis of product type, the market is sub-divided into manual, hydraulic and electric micromanipulators. The growth of electric micromanipulators is expected to increase accuracy in movement and convenience. This factor may also lead to increase number of adoptions across a wide range. Based on end user, the micromanipulator market is categorized into hospitals and research laboratories. Hospitals are likely to emerge as large end user of micromanipulators. Apart from that, Hospitals may also create additional opportunities within the forecast period. Application wise, the global market for micromanipulators is segmented into cell, and industrial micromanipulation.

The report presented here is a complete evaluation of global micromanipulators market with large focus on market dynamics that includes market drivers, restraints, and trends and opportunities. It also offers geographical and other segmentation studies of the market.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=49974

One of the most lucrative opportunities in micromanipulators market could be created with the Increasing investment by private and public sector organizations for developing hospitals with advanced treatment facilities. More number of patients are likely to suffer from infertility and opt for options that will contribute to the growth of the micromanipulator market.

With the introduction of laser application in medical equipment, scientists will be focusing on developing the reliability and quality of laser manipulators. This will then be suitable for throat, ears and other parts for minimally invasive procedures. While in the case of mechanical method alternative, for micromanipulation, optical tweezers technique were developed and is currently being used.

The global micromanipulators market could be classified into the regions of Europe, Asia Pacific, Middle East and Africa, Latin America, and North America. Among these, the region that is anticipated to secure a tremendous market revenue share is North America. This is due to the expanding investment by both private and government sector firms to introduce new and developed technology for treatment purpose. Apart from that, Asia pacific is also expected to show significant growth in the years to come.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=49974

Major companies operating in the global micromanipulators market are The Micromanipulator Company, Narishige Co. Ltd., Luigs & Neumann, World Precision Instruments Inc., and Siskiyou Corporation. Leading companies are looking forward to modify microscopic design for micromanipulators. This may boost the increasing utilization of micromanipulators globally.

IV Equipment Market to Register Substantial Expansion by 2026

2019-09-05T18:02:42.031Z

The demand within the global IV Equipment Market has been increasing on account of the rising incidence of chronic diseases that necessitate intravenous therapy. The field of medical sciences has been undergoing key advancements in recent times, and this has led to the induction of new healthcare devices and systems in mainstream medicine. Intravenous therapy refers to the use of infusions to deliver desired liquid medications to the veins. In common terms, intravenous infusions are known as drips and are extensively used across hospitals and healthcare centers. The need to administer timely medications to patients suffering from severe diseases has been driving demand within the global market for IV devices. Although drips are an easy way of administering the desired liquids into the body, several new IV devices have also come to the fore in recent times. Moreover, correction of electrolyte imbalances and fluid replacement therapies are also carried out with the help of IV therapy.

The global IV equipment market is segmented on the basis of product type, end-user, and region. All of these segments play a pivotal role in categorizing various growth parameters of the global IV equipment market.

A report added by Transparency Market Research (TMR) on the global IV equipment market sheds light on several key drivers of market demand. The primary intent behind the report is to offer a scale of judgement for market growth in the forthcoming years.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=49953

Blood transfusions have become common across the medical and healthcare industry, majorly due to the rising incidence of diseases that result in blood loss. Since intravenous therapies largely help in performing blood transfusion treatments, the demand within the global market for IV equipment is projected to reach new heights. Furthermore, patients suffering from severe diseases and disorders often struggle in oral intake of food, medication, or liquids. In such cases, IV equipment helps in administering the right doses of medication to the patients. This factor, coupled with the rising incidence of cancers, cardiovascular illnesses, and tumours, has created tremendous demand within the global market for IV equipment in recent times.

In recent times, various types of IV equipment with enhanced quality and performance have become available in the market. As these devices and equipments prove to be effective in carrying out blood transfusions and other intravenous procedures, more number of healthcare units and hospitals are projected to buy them. Despite these favourable factors for market growth, the high costs and risks associated with the use of IV equipment could hamper market growth.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=49953

The demand for IV equipment market has risen by leaps and bounds in North America, majorly due to the wellness of the healthcare sector in the US and Canada. Furthermore, the proficiency and skill of doctors and medical professionals in these countries has helped in easy administration of intravenous therapies. It is projected that the market for IV equipment in Asia Pacific would expand due to growth of medical tourism to countries such as China, Indonesia, and India.

Some of the key players in the global IV equipment market are Baxter International Inc., ICU Medical, Smiths Group, C. R. Bard, Moog Inc., and Terumo Corporation.

Medical Cyclotrons Market to Reflect Impressive Growth Rate by 2026

2019-09-05T18:02:37.035Z

A new era of nuclear medicine diagnosis has dawned with introduction of medical cyclotron technology. Medical cyclotron primarily produces positron emitters, which can be used in molecular imaging of organs. In medical cyclotron, particles such as deuterons and protons are accelerated and bombarded to an appropriate target material for the production of positron-emitting radioisotopes. Positron emitters are produced by the (p, α), (p, n) or (d, n) reaction.

View Report -

https://www.transparencymarketresearch.com/medical-cyclotrons-market.html

The neutron activation of the surrounding medium is of utmost importance while determining radiation safety. Medical cyclotrons are compact cyclotrons that are used for PET imaging through the production of positron-emitting radionuclides. Most of the clinically and medically useful positron emitters are formed by nuclear reactions consisting of low energy particles which are otherwise known as the compact cyclotrons. These cyclotrons are commercially available and utilize small space. The medical cyclotron operation can be controlled by computer. The cyclotron was invented by Ernest Lawrence and M.S. Livingstone of the University of California, Berkley, where it was first operated in 1932.

According to Radiological Society of North America, in 2013, the Canada government initiated the US$ 25 Mn, four-year Isotope Technology Acceleration Program (ITAP) for the further advancement of cyclotron and linear accelerator technologies for the production of Tc-99m. Grants for cyclotron projects were awarded at the TRIUMF and University of Alberta. In early 2015, TRIUMF announced that researchers had demonstrated a technology that can be feasible for a number of different cyclotrons, which are capable of serving reasonably large population centers. In 2018, according to a review by MDPI Journal, near 70% of the cyclotrons disseminated over the world are low-energy cyclotrons (≤20 MeV).

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=49911

Cancer has a major impact on society in the U.S. and across the world. Rise in prevalence of cancer is driving the medical cyclotrons market. According to National Cancer Institute, the estimated national expenditure for cancer care in the U.S. was US$ 147.3 Bn in 2017. In forecast period, the costs of cyclotrons are likely to increase due to increasing prevalence of cancer and rising elderly population. Costs are also likely to increase, as new and costly treatment are being adopted as standard of care. Rise in production of artificial radionuclides, increase in the number of treatments and medical care expenditure, surge in prevalence of cancer, lifestyle changes, increase in the number of geriatric population drive the global medical cyclotrons market. High operating and maintenance costs of cyclotrons, industrial and regulatory constraints, and narrow physician referral bases are expected to hinder the medical cyclotrons market during the forecast period.

Based on product type, the global medical cyclotrons market can be classified into ring cyclotrons and azimuthally varying field (AVF) cyclotron. In terms of end-users, the global medical cyclotrons market can be segmented into hospitals, specialized clinics, pharmaceutical companies and others.

Based on region, the global medical cyclotrons market can be segregated into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. North America is expected to lead the medical cyclotrons market due to factors such as effective government initiatives, increase in business investments, and developed economy. Latin America is expected to account for a large share of the medical cyclotrons market due to increasing awareness.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=49911

Key players operating in the global medical cyclotrons market include Cyclotron Products, Nuclear Healthcare Limited, Sumitomo Heavy Industries. Ltd., IBA, General Electric Company, Best Medical International, Inc., and TeamBest. These players engage in various strategies, such as agreements, partnerships, collaborations, and new product launches, to gain competitive advantage in the market.

Fecal Occult Testing Market to Receive Overwhelming Hike in Revenues by 2026

2019-09-05T18:02:32.055Z

Fecal occult blood test (FOBT) is a diagnostic screening test used to analyze hidden (occult) blood in stool samples. Fecal occult blood test is also commonly known as Hemoccult, Stool Occult Blood, Guaiac Smear Test gFOBT, Immunoassay FOBT, Immunochemical FOB, and iFOBT. These tests are used to detect polyps in the colon or rectum or polyps bleed. Fecal occult blood test is majorly used for screening of colon cancer and analyzing possible causes of unexplained anemia. Colon cancer is large intestine (colon) cancer, which occurs in the lower part of the digestive system. Colon cancer generally arises with a small, benign cluster of cells, known as adenomatous polyps, which result in colon cancer.

Increasing incidence of colon cancer and rectal cancer, favorable initiatives by non-profit organizations and governments for colorectal cancer check-up programs, and rise in adoption of direct-to-consumer laboratory testing are the major factors driving the growth of the global Fecal Occult Testing Market. Also, increasing awareness regarding quick and accurate cancer diagnosis is boosting the demand for fecal occult blood tests. Colon cancer is a big concern for various developed and developing countries. Diagnosis of colon cancer at an early stage can help in controlling mortality.

Availability of fecal occult blood test products in online stores and improvement in direct-to-consumer laboratory testing are the trending factors expected to provide lucrative growth opportunities to the fecal occult testing market during the forecast period. However, high cost associated with fecal occult blood test products and low awareness regarding the test in undeveloped countries restrain the growth of the market. Low health care expenditure in underdeveloped countries and increase in awareness about health care diagnostic services have prompted patients toward cost-effective alternatives for diagnosis. This has been a major restraining force for the fecal occult testing market in developing as well as underdeveloped economies.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45441

The fecal occult testing market can be segmented based on product, end-user, and geography. In terms of product, the fecal occult blood test market can be categorized into Immuno-FOB agglutination test, guaiac FOB stool test, lateral flow immuno-FOB test, and immuno-FOB ELISA test. Based on end-user, the fecal occult testing market can be divided into hospitals, clinical diagnostic laboratories, and physicians' office laboratories. Geographically, the fecal occult blood test market can be classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America dominated the global fecal occult testing market due to well-spread awareness among people, along with rapidly increasing demand for technologically advanced fecal occult blood test products. The U.S. is the major contributor of the fecal occult testing market in North America, having the adoption rate of point-of-care testing products. North America occupies a substantially large market share of the global fecal occult blood test market, followed by Europe. Increase in demand for fecal occult blood test products from European countries such as U.K., Germany, and France. Increasing prevalence of colon cancer is the major factor of the growth of the fecal occult testing market.

In Asia Pacific, increasing demand for fecal occult blood test products from countries such as India, China, and Japan is expected to boost the fecal occult testing market. In addition, increase in incidences of colon cancer and rise in awareness regarding cancer screening tests are some of the key factors driving the fecal occult testing market in the region. However, affordability and lack of availability of innovative fecal occult blood test products have become a restraining factor for the market in developing and undeveloped regions, such as, Middle East & Africa and Latin America. Despite of this, the fecal occult testing market in these regions is expected to witness a slow growth with contribution from developing countries such as Brazil and South Africa. Latin American countries, such as, Mexico and Brazil, are expected to exhibit considerable potential for the fecal occult testing market.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=45441

Major players operating in the fecal occult blood test market include Abbott Laboratories, Biohit Oyj., Quidel Corporation, Randox Laboratories Ltd., Epigenomics AG, Beckman Coulter, Inc., Polymedco CDP, LLC, Quest Diagnostics Incorporated, EIKEN CHEMICAL CO., LTD., and EDP Biotech.

Whipple’s Disease Market Poised to Expand at a Robust Pace by 2025

2019-09-05T18:02:28.047Z

Whipple’s disease is a rare bacterial infection caused by bacteria called Tropheryma whipplei (T. whipplei) that primarily affects the small intestine. Bacterial infection can cause thickening of tissues in the small intestine and internal sores. Bacterial infection could affect many different organs of the body such as gastrointestinal system, central nervous system, joints, heart, lungs, and eyes, and interfere with the body's ability to metabolize fats. Whipple’s disease can be fatal, if left untreated.

Global incidence of the Whipple’s disease is 1 in 1 million people. Most of the reported cases are from North America and Europe. The disease is most common in Caucasian men, with a mean age of 50 years. The disease rarely affects women. The symptoms of the disease appears to be most common in farmers, as the bacteria are found in soil and sewage waste water. Very few cases of the disease have been reported to date due to genetic factors from the same family and inter-human transmission cases.

High rate of growth of the Whipple’s Disease Market can be attributed to the entry of novel, highly priced therapies and high unmet needs. More highly-priced therapies are expected during the forecast period. Kalydeco for cystic fibrosis and exon-skipping therapies for duchenne muscular dystrophy are the new therapies introduced in the market. Competitive activity is increasing as larger companies realize the rewards of investing in orphan therapeutics. High unmet needs and low competition in several regions is expected to attract more companies to the market in the near future. The clinical studies for the molecules receiving the funding from the U.S. government for the rare disease lead to increase in development of molecules. The global Whipple’s disease market can be segmented based on type of diagnosis, type of treatment, and end-user.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45084

In terms of type of treatment, the global Whipple’s disease market can be divided into medications, supplements, and others. The medications segment can be classified into ceftriaxone (Rocephin), meropenem (Merrem I.V.), penicillin G (Pfizerpen), streptomycin (Streptomycin), doxycycline (Vibramycin), trimethoprim with sulfamethoxazole (Septra, Bactrim), and hydroxychloroquine (Plaquenil), and others. The supplements segment can be categorized into vitamin supplements, iron supplements, mineral supplements, and others.

In terms of type of diagnosis, the global Whipple’s disease market can be segmented into non-specific diagnosis, specific diagnosis, and indirect diagnosis. Non-specific diagnosis includes physical exam, blood tests, endoscopy, histologic study by specific staining, and electron microscopy. Specific diagnosis includes immune-histochemical diagnosis, molecular diagnosis, and culture. Indirect diagnosis includes indirect immunofluorescence and enzyme-linked immunosorbent assay.

Geographically, the Whipple’s disease market is segmented in five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for major share of the Whipple’s disease market. According to Research Office Legislative Council Secretariat report there are over 30 million people suffering from rare diseases in the U.S. The strong focus on research and development, the government aids to promote R&D, such as research grants, tax credits and fee waivers contribute to the growth of the market. As a result, over 4,171 drugs have been designated orphan drug status in the U.S. as of June 2017. In addition, favorable reimbursement offered by the government and private payers for the treatment of rare diseases contributes to the market growth in the region.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=45084

Europe was the trailing second region in terms of revenues in orphan drugs market. According to Research Office Legislative Council Secretariat report 2015, over 30 million peoples were suffering from rare diseases in the European Union. The incentives offered to promote the manufacturing of orphan drugs in the region, such as 10-year period of marketing exclusivity, research grants and reduced fees for marketing authorization applications aid in the growth of the market. Over 1,805 drugs have been granted orphan drug status in the European Union and over 128 drugs were granted marketing authority during 2000 to 2016.

Geographically, the global Whipple’s disease market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Players operating in the global market are F. Hoffmann-La Roche Ltd., Pfizer, Inc., Bristol-Myers Squibb Company, and Sun Pharmaceutical Industries Limited.

Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market Foreseen to

2019-09-05T18:02:24.025Z

Gastroenteropancreatic neuroendocrine tumors are a large and differing group of uncommon and complex neoplasms. Most gastroenteropancreatic neuroendocrine tumors are sporadic. Early diagnosis of gastroenteropancreatic neuroendocrine tumors is difficult because of their heterogeneity and remarkable attributes. This increases the probability of metastatic ailment and diminishes the extent of remedial potential outcomes.

Gastroenteropancreatic neuroendocrine tumors are also called carcinoids and islet cell tumors. These tumors are generally derived from neuroendocrine cells that can occur anyplace along the gastrointestinal tract and contain a heterogeneous group of neoplasms with a wide and complex range of molecules. Gastroenteropancreatic neuroendocrine tumors have customarily been classified into mid-gut, foregut, and hindgut. The special feature of the tumors is the ability to synthesize, store, and secrete peptides, hormones, and neuroamines. Gastroenteropancreatic neuroendocrine tumors are most localized in the gastric mucosa, intestine, rectum, and the pancreas. Abdominal pain, weight loss, anorexia, jaundice, intra-abdominal mass, and bleeding are some of the symptoms of gastroenteropancreatic neuroendocrine tumors. Suitable diagnosis and treatment of neuroendocrine tumors come out through joint effort by utilizing particular biochemical, radiologic, and surgical techniques.

Based on therapy, the global Gastroenteropancreatic Neuroendocrine Tumor Therapeutics Market can be categorized into chemotherapy, peptide-receptor radionuclide therapy, and others. The chemotherapy segment is likely to grow at a rapid pace during the forecast period because the patient’s recovery response rate through chemotherapy treatment is high as compared to other therapies. Moreover, chemotherapy is well tolerated, with minimal side effects such as nausea, and abdominal pain. In terms of drug, the global treatment market can be classified into lutathera, sunitinib, everolimus, and others. The lutathera segment is expected to expand at a rapid pace during the forecast period because lutathera is a radiolabeled molecule that binds to the specific receptors of the tumor and stop its growth in a short time as compared to other drugs.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45000

Increase in geriatric population and rise in prevalence of colorectal cancer are the major factors fueling the growth of the global gastroenteropancreatic neuroendocrine tumors therapeutics market. However, side effects associated with drugs such as nausea, vomiting, and long treatment procedures are likely to restrain the market in the next few years.

In terms of region, the global gastroenteropancreatic neuroendocrine tumor therapeutics market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market. The region is projected to account for a significant share of the global market during the forecast period, due to rise in prevalence of small intestine cancer and colorectal cancer. According to the American Cancer Society, more than 10,000 people were effected with some type of small intestine cancer in 2017.

Increase in the geriatric population and favorable reimbursement policy for the treatment of gastroenteropancreatic neuroendocrine tumors are projected to drive the market in Europe. Rise in prevalence of digestive cancer and increase in awareness about screening test to detect early tumors or cancer are anticipated to propel the market in Asia Pacific during the forecast period. Surge in awareness about the harmful effects of gastroenteropancreatic neuroendocrine tumors and high diagnosis rates are likely to augment the gastroenteropancreatic neuroendocrine tumors therapeutics market in Middle East & Africa during the forecast period.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=45000

Key players operating in the global gastroenteropancreatic neuroendocrine tumor therapeutics market are Novartis, Pfizer, Inc., Fresenius Kabi, Teva Pharmaceutical, and Sun Pharma, among others.

Acquired Methemoglobinemia Treatment Market to Witness an Outstanding Growth by 2026

2019-09-05T18:02:20.027Z

Methemoglobinemia is a condition when more than 1% of hemoglobin in the blood gets oxidized to methamoglobin, which is an abnormal form of hemoglobin unable to bind the oxygen molecules. The iron atom gets oxidized from the ferrous state (Fe2+) to the ferric state (Fe3+), losing an electron to an oxidant. This results in anemia, cyanosis, dizziness, fatigue, headache, dyspnea on exertion, and tachycardia. When the levels of methamoglobin in the blood exceeds 50%, it can cause dysrhythmias, hypotension, acidosis, coma, and death. The two common causes of methemoglobinemia are genetic and acquired.

Acquired methemoglobinemia is caused by exposure to certain oxidizing substances that lead to the conversion of hemoglobin to methemoglobin. For instance, anilines, dyes, nitrates and nitrites, and medications including lidocaine, prilocaine, benzocaine, chloroquine, and dapsone. Rise in incidence of acquired methemoglobinemia owing to increase in use of local anesthetics, surge in use of silver nitrates for the treatment of wounds, eating nitrate rich vegetables, and growing awareness about the available treatments are the factors expected to drive the global Acquired Methemoglobinemia Treatment Market during the forecast period. High cost of blood products and lack of trained physicians in rural areas are the factors likely to restrain the global acquired methemoglobinemia treatment market.

The global acquired methemoglobinemia treatment market can be segmented based on type of treatment, end-user, and region. In terms of type of treatment, the global market can be categorized into drug therapy, blood transfusion therapy, and oxygen therapy. The drug therapy segment can be classified into methylene blue, dextrose, and ascorbic acid treatment. The methylene blue sub-segment is anticipated to dominate the drug therapy segment during the forecast period due to its positive performance to reverse the condition.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=44940

Based on end-user, the global acquired methemoglobinemia treatment market can be divided into hospitals, clinics, and ambulatory care centers. The hospitals segment is expected to account for the major market share during the forecast period, attributed to patient preference for hospitals to treat such emergency cases and availability of equipment at hospitals such as oxygen therapy and blood transfusion devices. The clinics segment is expected to expand at the highest CAGR from 2018 to 2026.

Geographically, the global acquired methemoglobinemia treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the market due to availability of advanced therapeutic options to treat the disease, high health care awareness among the population, and high health care expenditure. The market in Asia Pacific is expected to expand at the highest CAGR due to increasing use of local anesthetics, rise in health care awareness, and surge in health care spending. High use of antibiotics such as dapsone and chloroquine to treat infections is responsible for rise in incidence of acquired methemoglobinemia in the region. Moreover, poor sanitation in Middle East & Africa, Latin America, and some parts of the Asia also contribute towards the increasing incidence of acquired methemoglobinemia in these regions. This is expected to further drive the growth of the global acquired methemoglobinemia treatment market during the forecast period.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=44940

Key players operating in the global acquired methemoglobinemia treatment market include GlaxoSmithKline plc, Mylan N.V., American Regent, Inc., Teligent, Inc., Provepharm Life Solutions, McGuff Company, Inc., Abundance Naturally Limited, Kedrion Biopharma, Inc., and Octapharma.

Wellness Tourism Market to Experience a Swift Development by 2026

2019-09-05T18:02:10.116Z

Wellness tourism involves travel with the aim of facilitating well-being and good health through psychological, spiritual, or physical activities. Wellness tourism differs markedly from medical tourism. The former involves tourism focused on prevention of diseases and maintaining quality of life, whereas the latter generally involves travel for the purpose of receiving treatment for a diagnosed disease or medical condition. Wellness tourism encompasses diverse industries that enable consumers to incorporate wellness into their daily lives. These products and services help consumers extend wellness to their homes and work environments with their daily activities such as having food and exercise.

A key factor driving the global Wellness Tourism Market is the rise in disposable incomes, particularly in developing countries, owing to rapid growth of economies of these countries. Higher income levels have also shifted the trend toward increased discretionary spending, particularly on wellness goods and services. According to certain estimates, the average per capita disposable income in the Asia Pacific region increased by 19.3% from 2007 to 2012, which is slated to increase by 35.2% till 2020. Surge in the disposable income is expected to boost the demand for wellness tourism due to rise in the number of health-conscious people.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45141

The growing burden of chronic diseases is a prominent factor promoting the growth of the global wellness tourism market. The increase in urbanization fueled by rapid economic growth has led to unbalanced diets and sedentary lifestyle. This, in turn, has augmented the prevalence of lifestyle-associated diseases such as obesity, diabetes, and high cholesterol. According to a study conducted by the Institute for Health Metrics & Evaluation (IHME), a global health research organization, in 2013, approximately 30% of the global population is either overweight or obese.

The rise in disposable incomes is raising expenditure on fast food or junk food, causing surge in the prevalence of diseases such as diabetes. According to the World Health Organization (WHO), the number of individuals with diabetes worldwide increased to 422 million in 2014 from 108 million in 1980. The rate of prevalence of diabetes in people aged above 18 years has risen to 8.5% in 2014 from 4.7% in 1980. The WHO estimates that diabetes is projected to be the seventh leading cause of deaths worldwide by 2030.

Additionally, people in countries such as the U.S., Brazil, and Mexico are increasingly resorting to wellness procedures such as beauty treatments, anti-aging treatments, weight loss programs, spa therapies, and yoga programs in order to boost their physical as well as mental well-being. The popularity of these programs coupled with the rise in stress levels is expected to propel the global wellness tourism market during the forecast period. On the other hand, shortage of facilities (for example, lack of adequate infrastructure and skilled and trained workers) in developing countries is expected to impede the market during the forecast period.

The global wellness tourism market can be segmented based on service type and geography. In terms of service type, the market can be divided into beauty & anti-aging, health & nutrition, fitness & weight management, preventive & personalized medicine, complementary & alternative medicine, spa industry, workplace wellness, and others.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=45141

Geographically, the global wellness tourism market can be segregated into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global wellness tourism market, due to high expenditure on wellness by consumers in the region. North America is followed by Europe and Asia Pacific. Rising disposable income of people in countries such as China, India, and Indonesia is propelling the wellness tourism market in Asia Pacific.

Prominent players operating in the global wellness tourism market are Four Seasons Hotels Limited, Hilton Worldwide, KPJ Healthcare Berhad, VLCC Health Care Limited, Hyatt Hotels Corporation, and Marriott International, Inc.

Antibiotic Microsphere Beads Market to Expand at an Impressive Rate by 2026

2019-09-05T18:02:05.102Z

Antibiotic microsphere beads are small, time release antibiotic beads that proceed to release antibiotics over a period of time once implanted or inserted inside the body to fight infection when it is most needed. Terry Clyburn, M.D, at Houston Methodist ?rth?pedics and Sports Medicine developed these tiny antibiotic beads, which are as small as grains of salt, to aid in combating infections. He has been working for over 15 years to perfect these microspheres.

View Report -

https://www.transparencymarketresearch.com/antibiotic-microsphere-beads-market.html

There is a risk of infection involved post any surgery. However, if there are post-surgery infections after joint replacement surgeries, these are harder to treat as the implants are not linked to the body’s blood flow. Hence, the medication sent to fight the infection cannot reach and target the bacteria in the implant. Therefore, usually the patients undergoing joint replacement are placed on intravenous antibiotics prior to and after the surgery to reduce the incidence of infection.

Antibiotic microsphere beads can be coated on to the implant itself prior to placing it in the patients joint owing to which the antibiotics are delivered straight to the surgical site, which aids in preventing an infection from developing. Once implanted at the site, the antibiotic microsphere beads are devised to release antibiotics at a level that is high enough to treat infections for at least the next three to six weeks. This is a time frame when infections are most likely to erupt.

Request to View Brochure of Report -

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=45087

There is another medication that is classified as time release medication, which in most cases releases the drug once the outer protective covering is dissolved inside the body. However, these antibiotic microspheres are truly extended time release, as these have multiple layers that dissolve over time and deliver medication over the implant and its surrounding tissues. Over a span of six weeks, the microspheres dissolve completely ensuring that the patient fights off infections, leaving no residue behind that could be harmful to the patient. In order to test efficacy of these antibiotic microspheres, experiments were conducted where metal implants were knowingly infected with bacteria, and then coated in microspheres and inserted inside animal models.

There was no sign of infection in the implant coated with the antibiotic microspheres. According to a study, around 10,000 in over 1 million people who undergo total joint replacements annually will develop infections. Antibiotic microsphere beads can play a vital role in reducing the number of infections, by slowly releasing the antibiotic over several weeks to starve off infections. Infections that are caused post-surgery can manifest immediately post-surgery or sometimes weeks or years after the surgery. When the infection spreads and surpasses the superficial tissues and gains access deep into the replacement joint, it mostly requires a surgical intervention. The use of antibiotic microspheres will eliminate that.

Request to View ToC of the report –

https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=45087

Mr. Clyburn has produced the microspheres in collaboration with Catherine Ambrose, Ph.D., from UTHealth and Rice University's Antonios Mikos, Ph.D. Mr. Clyburn is seeking FDA approval of the antibiotic microspheres and estimates that the microspheres will be in use in around next three to eight years. Once these receive FDA approval, antibiotic microsphere beads are expected to considerably eliminate the chances of post joint replacement surgery infections, thereby saving the patient from possible complications and trauma.